Thus, the combination of AT1 receptor blockade with SGLT2 inhibition leads to a better prevention of Ang II-induced kidney damage compared with the effect of either AT1 receptor blockade or SGLT2 inhibition used as mono-therapy. This evidence concerns the gene AGTR1 and Nephropathy.